National Hospital for Neurology & Neurosurgery, UCL Institute of Neurology, Queen Square, London, UK.
Cell Stem Cell. 2024 Jan 4;31(1):5-6. doi: 10.1016/j.stem.2023.12.005.
Stem cell therapy for Parkinson's disease requires demonstration of safety and efficacy of dopaminergic cells derived from a cell line, consideration of dose, and whether this is deliverable at scale. Park et al. demonstrate these requirements for a new hESC line and that their manufacturing methods allow for its scalability.
帕金森病的干细胞治疗需要证明源自细胞系的多巴胺能细胞的安全性和有效性，考虑剂量，以及是否可以大规模提供。Park 等人证明了一种新的 hESC 系满足这些要求，并且他们的制造方法允许其可扩展性。
